The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Latest research and treatment of advanced-stage epithelial ovarian cancer
Open accessAbstract
The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics, despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free survival and overall survival, although the cure rates have been affected only modestly. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, growth in our armamentarium offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial 'ovarian' cancer and describes the direction and early results of clinical investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Self-citationBristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Self-citationSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Self-citationPfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Self-citationHoskins, W. J., McGuire, W. P., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M., Ball, H., & Berek, J. S. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70090-7 · Cited by 659
Yang, D., Khan, S., Sun, Y., Hess, K., Shmulevich, I., Sood, A. K., & Zhang, W. (2011) · JAMA · doi:10.1001/jama.2011.1456 · Cited by 599
Self-citationEarly versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
(1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)90219-8 · Cited by 553
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
Self-citationThe genesis and evolution of high-grade serous ovarian cancer
Bowtell, D. D. L. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2946 · Cited by 445
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Harter, P., Bois, A. D., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., Schröder, W., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9058-0 · Cited by 425
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Self-citationRose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386
Chi, D. S., McCaughty, K., Diaz, J. P., Huh, J., Schwabenbauer, S., Hummer, A. J., Venkatraman, E. S., Aghajanian, C., Sonoda, Y., Abu‐Rustum, N. R., et al. (2006) · Cancer · doi:10.1002/cncr.21845 · Cited by 350
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
Harter, P., Sehouli, J., Reuß, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., et al. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31820aaafd · Cited by 297
Dennis, S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitão, M. M., Levine, D. A., Gardner, G. J., Abu‐Rustum, N. R., & Barakat, R. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.014 · Cited by 294
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
Gershenson, D. M., Sun, C. C., Bodurka, D., Coleman, R. L., Lu, K. H., Sood, A. K., Deavers, M., Malpica, A. L., & Kavanagh, J. J. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.03.001 · Cited by 291
Self-citationFerrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6606 · Cited by 289
Markman, M., Blessing, J., Rubin, S. C., Connor, J., Hanjani, P., & Waggoner, S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.036 · Cited by 237
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer
Morrison, J., Haldar, K., Kehoe, S., & Lawrie, T. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005343.pub3 · Cited by 223
Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
Bottsford-Miller, J. N., Coleman, R. L., & Sood, A. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.9242 · Cited by 199
Self-citationKuo, K.-T., Guan, B., Feng, Y., Mao, T.-L., Chen, X., Jinawath, N., Wang, Y., Kurman, R. J., Shih, I.-M., & Wang, T.-L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3913 · Cited by 196
Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0755 · Cited by 189
Miller, D. S., Blessing, J. A., Krasner, C. N., Mannel, R. S., Hanjani, P., Pearl, M. L., Waggoner, S. E., & Boardman, C. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2963 · Cited by 186
Eisenhauer, E. L., Abu-Rustum, N. R., Sonoda, Y., Aghajanian, C., Barakat, R. R., & Chi, D. S. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.022 · Cited by 178
The Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 169
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Wang, Z. C., Birkbak, N. J., Culhane, A. C., Drapkin, R., Fatima, A., Tian, R., Schwede, M., Alsop, K., Daniels, K. E., Piao, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0857 · Cited by 160
Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1193 · Cited by 159
Rose, P. G., Blessing, J. A., Ball, H. G., Hoffman, J. S., Warshal, D. P., DeGeest, K., & Moore, D. H. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00091-4 · Cited by 156
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Self-citationJelliffe, R. W. (2002) · American Journal of Nephrology · doi:10.1159/000065221 · Cited by 144
Rosenberg, P., Andersson, H., Boman, K., Ridderheim, M., Sorbe, B., Puistola, U., & Parö, G. (2002) · Acta Oncologica · doi:10.1080/028418602320404998 · Cited by 137
Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
Tay, E. H. (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)01977-4 · Cited by 124
Coleman, R. L., Brady, W. E., McMeekin, D. S., Rose, P. G., Soper, J. T., Lentz, S. S., Hoffman, J. S., & Shahin, M. S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.03.036 · Cited by 122
Self-citationVergote, I. B., Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C., Colombo, N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5669 · Cited by 121
Singer, G., Shih, I., Truskinovsky, A. M., Umudum, H., & Kurman, R. J. (2003) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200301000-00009 · Cited by 113
Ovarian cancer: a focus on management of recurrent disease
Herzog, T. J., & Pothuri, B. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0637 · Cited by 112
Self-citationMaintenance chemotherapy for ovarian cancer
Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., Wang, X., Zhou, J., & Feng, D. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007414.pub3 · Cited by 95
Secondary Cytoreductive Surgery in Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Panici, P. B., Vivo, A. D., Bellati, F., Manci, N., Perniola, G., Basile, S., Muzii, L., & Angioli, R. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9273-8 · Cited by 95
Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer.
Vergote, I. B., Wever, I. D., Decloedt, J., Tjalma, W. A. A., van Gramberen, M., & van Dam, P. A. (2000) · PubMed · Cited by 92
Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental
Gore, M. E., du Bois, A., & Vergote, I. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0376 · Cited by 81
Vergote, I. B., Trope, C. G., Amant, F. C., Ehlen, T., Reed, N. S., & Casado, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9785 · Cited by 74
WU, R. T., Hu, T. C., Rehemtulla, A., Fearon, E. R., & Cho, K. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1388 · Cited by 71
Oza, A. M., Cibula, D., Oaknin, A., Poole, C. J., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.5001 · Cited by 66
Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
Monk, B. J., & Coleman, R. L. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c104fa · Cited by 65
Self-citationHata, K., Nakayama, K., Fujiwaki, R., Katabuchi, H., Okamura, H., & Miyazaki, K. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.031 · Cited by 64
Clarke, T., Galaal, K. A., Bryant, A., & Naik, R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006119.pub3 · Cited by 63
Brewer, C. A., Blessing, J. A., Nagourney, R. A., Morgan, M. A., & Hanjani, P. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.03.018 · Cited by 61
Markman, M. M., Hakes, T. B., Reichman, B. S., et al. (1992) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01209489 · Cited by 55
Fleming, N. D., Cass, I. A., Walsh, C., Karlan, B. Y., & Li, A. J. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.014 · Cited by 54
Strait, K. A., Warnick, C. T., Ford, C. D., Dabbas, B., Hammond, E. H., & Ilstrup, S. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0107 · Cited by 54
Targeting angiogenesis in ovarian cancer
Schmitt, J., & Matei, D. E. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.004 · Cited by 53
du Bois, A., Marth, C., Pfisterer, J., Harter, P., Hilpert, F., Zeimet, A. G., & Sehouli, J. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31821d419a · Cited by 37
Lee, C. K., Simes, R. J., Brown, C. S. B., Lord, S. J., Wagner, U. A. G., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.364 · Cited by 36
Personalized cancer medicine—advances and socio-economic challenges
Jackson, D., & Sood, A. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.151 · Cited by 35
Self-citationMaintenance chemotherapy for ovarian cancer
Mei, L., Chen, H., Wei, D. M., Fang, F., Liu, G. J., Xie, H. Y., Wang, X., Zou, J., Han, X., & Feng, D. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007414.pub2 · Cited by 34
Preoperative Predictors for Residual Tumor after Surgery in Patients with Ovarian Carcinoma
Jong, D. D., Eijkemans, M. J. C., Fong, S. L., Gerestein, C. G., Kooi, G. S., Baalbergen, A., van der Burg, M. E. L., Burger, C. W., & Ansink, A. C. (2007) · Oncology · doi:10.1159/000113051 · Cited by 33
Monk, B. J., Dalton, H., Benjamin, I., & Tanovı́c, A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802002814 · Cited by 33
Self-citationSallinen, H., Anttila, M., Gröhn, O. H. J., Koponen, J., Hämäläinen, K. M., Kholová, I., Kosma, V., Heinonen, S., Alitalo, K. K., & Ylä‐Herttuala, S. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.56 · Cited by 20
Kapiriri, L., Lavery, J. V., SINGER, P. A., Mshinda, H., Babiuk, L. A., & Daar, A. S. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-811 · Cited by 17
Lu, S., & Lu, X. (2012) · PubMed Central · Cited by 6
Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management
Markman, M. M. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0121-4 · Cited by 4
Hill, T. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2012.248 · Cited by 4
Cited by
He, C., Lu, K., Liu, D., & Lin, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4098862 · Cited by 885
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.012 · Cited by 740
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Self-citationInvasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Metadata
- Authors
- Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-02-05
- Volume
- 10
- Issue
- 4
- Pages
- 211-224
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2068854353
- Cited by
- 489
- References
- 94
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.